Myllia Biotechnology GmbH

Founded

2018

Staff

26

Organization type

RDM biotech/pharma

Cluster

LISAvienna

At Myllia, we perform pooled CRISPR screens and functional genomics at scale in advanced cellular models to map the impact of thousands of genetic perturbations at single-cell resolution – a new paradigm to nominate the best possible targets for your drug discovery campaign. Pooled CRISPR screens accelerate drug discovery across many therapeutic areas and help unravel gene regulatory networks in cancer cells and primary human T cells.

R&D:Pooled CRISPR screens to uncover novel insights relevant for drug target identification and to support target validation in drug discovery programs.

Services:Target identification is the first step of a drug discovery campaign and begins with high-content screening to identify possible ‘druggable’ targets and their role in the respective disease. Myllia’s unique CROP-Seq (Perturb-Seq) technology for phenotypic screening in combination with the best available cellular models (including cancer cells and primary T cells) supports the identification and validation of critical genes and pathways driving certain disease states.